Oruka Therapeutics, Inc.
NASDAQ:ORKA · NASDAQ Global Market
+$0.46 today
Vol 2.99M · Avg 1.55M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-22.3%
avg -57.2%
ROIC
-25.8%
avg -58.5%
ROA
-21.6%
avg -50.9%
Analysis
ROA is currently the strongest return metric at -21.6% versus its period average of -50.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Lawrence Otto Klein | President, Chief Executive Officer & Director | $1.08M | — | 43 | $925,580.00 | 2.47% |
Joana Goncalves | Chief Medical Officer | $730,980.00 | — | 52 | $37,165.00 | 0.10% |
Paul T. Quinlan | General Counsel & Secretary | $730,980.00 | — | 63 | $31,034.00 | 0.08% |
Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls | — | — | — | — | — |
Alan Lada | VP of IR & Capital Markets | — | — | — | — | — |
Arjun Agarwal | Senior Vice President of Finance & Treasurer | — | — | 50 | $16,899.00 | 0.05% |
Christopher Finch | Senior VP and Head of Business Development & Strategy | — | — | — | $35,000.00 | 0.09% |
Laura Sandler | Chief Operating Officer | — | — | 48 | $236,384.00 | 0.63% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
53
$13.58M
Net Sentiment
$13.58M
Net selling
Most Active
Goncalves Joana
22 transactions
1–10 of 53
Analysis
Insiders reported 0 buys worth $0.00 and 53 sells worth $13.58M over the last 12 months. That adds up to net selling of $13.58M. Goncalves Joana was the most active insider with 22 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.40B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.91B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.60B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
$1.35B
Xencor, Inc.
NASDAQ:XNCR
$937.70M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$858.23M
Oculis Holding AG
NASDAQ:OCS
$642.01M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$605.61M
Who manages ORKA?
Oruka Therapeutics, Inc. (ORKA) lists 8 active executives. The top listed executive is Joana Goncalves, Chief Medical Officer.
Are ORKA insiders buying or selling?
Recent insider activity shows net buying of $15.14M.
Explore More
Continue the stock analysis
Jump to another research area for this company.